Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + trastuzumab + mFOLFOX6 versus standard of care in first-line HER2-positive metastatic colorectal cancer
NL-OMON59071Phase 3Recruiting
- Sponsor
- Seagen Inc.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tucatinib in colorectal cancer (CRC), sponsored by Seagen Inc. Primary endpoint: Progression-free survival per BICR. Started Aug 2023; status: recruiting.
02
Drugs
tucatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON59071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59071.